Fiche publication

Date publication

janvier 2020

Journal

European journal of heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick


Tous les auteurs :
Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F, Cleland JGF

Résumé

Asymptomatic patients with coronary artery disease (CAD), hypertension and/or type 2 diabetes mellitus (T2DM) are at greater risk of developing heart failure (HF). Fibrosis, leading to myocardial and vascular dysfunction, might be an important pathway of progression. The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3.

Mots clés

Biomarkers, Fibrosis, HOMAGE, Spironolactone, Study design

Référence

Eur. J. Heart Fail.. 2020 Jan 16;:

Fiche publication

Retrouvez aussi

Personnes
Equipes
Plateformes
Unités de recherche, établissements
Projets de recherche
Publications scientifiques